Equity · Healthcare
NBIX
NASDAQNeurocrine Biosciences (NBIX)
The line runs 155.56 USD on 19 August through 157 USD on 10 September, on a scale from 152 to 160. Days the market did not trade hold the previous close, flat.
- Market cap
- 15.9B USD
- P/E (TTM)
- 23.3
- Revenue, year to Dec 2025
- 2.9B USD
- EPS, diluted, year to Dec 2025
- 4.67 USD
- 52-week range
- 123 USD – 181 USD
- Avg volume
- 113.6K
as of Sep 10, 2026
Have Neurocrine Biosciences (NBIX) insiders bought or sold shares recently?
In the 90 days to 17 Nov 2026, Neurocrine Biosciences insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase.
Form 4, 90 days to 17 Nov 2026, newest reported trade 3 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | MORROW GEORGE JDirector | Sell | 7,200 | 1.2M USD |
| 02 Nov 2026 | MORROW GEORGE JDirector | Sell | 7,500 | 1.1M USD |
| 30 Oct 2026 | MORROW GEORGE JDirector | Sell | 300 | 45K USD |
| 14 Sep 2026 | ABERNETHY MATTChief Financial Officer | Sell | 2,311 | 363K USD |
| 14 Sep 2026 | Boyer David W.Chief Corp. Affairs Officer | Sell | 826 | 130K USD |
| 09 Sep 2026 | BENEVICH ERICChief Commercial Officer | Sell | 2,154 | 333K USD |
| Sold | 6 open-market sales | 20,291 | $3.16M |
27 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | MORROW GEORGE JDirector | Option exercise | 7,200 | 386K USD |
| 02 Nov 2026 | MORROW GEORGE JDirector | Option exercise | 7,500 | 402K USD |
| 01 Nov 2026 | Gano KyleChief Executive Officer | Option exercise | 614 | |
| 01 Nov 2026 | Gano KyleChief Executive Officer | Tax withheld | 332 | 49K USD |
| 30 Oct 2026 | MORROW GEORGE JDirector | Option exercise | 300 | 16K USD |
| 11 Sep 2026 | ABERNETHY MATTChief Financial Officer | Award | 5,020 | |
| 11 Sep 2026 | ABERNETHY MATTChief Financial Officer | Tax withheld | 2,709 | 423K USD |
| 11 Sep 2026 | BENEVICH ERICChief Commercial Officer | Award | 6,275 | |
| 11 Sep 2026 | BENEVICH ERICChief Commercial Officer | Tax withheld | 3,386 | 529K USD |
| 11 Sep 2026 | Boyer David W.Chief Corp. Affairs Officer | Award | 3,587 | |
| 11 Sep 2026 | Boyer David W.Chief Corp. Affairs Officer | Tax withheld | 1,936 | 302K USD |
| 11 Sep 2026 | Cooke JulieChief Human Resources Officer | Award | 3,587 |
Showing the 12 most recent of 27 compensation filings in this window. The figures above count all of them.
Which funds hold Neurocrine Biosciences (NBIX)?
12 of the 45 institutional funds we track reported a Neurocrine Biosciences position for the quarter ended 30 Sep 2026 — a combined 937.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 3,062,385 | 422.5M USD | −19.8% |
| Renaissance Technologies | Held (±25%) | 2,300,697 | 326.3M USD | −1.5% |
| Man Group | Held (±25%) | 474,287 | 67.3M USD | −21.1% |
| Millennium Management | Added | 368,839 | 52.3M USD | +3,083.8% |
| Bridgewater Associates | Held (±25%) | 206,386 | 29.3M USD | +0.3% |
| Balyasny Asset Management | New position | 139,937 | 19.8M USD | |
| Two Sigma Investments | Trimmed | 76,780 | 10.9M USD | −96.3% |
| Citadel Advisors | Added | 36,382 | 5.2M USD | +206.7% |
| Fisher Asset Management | Trimmed | 16,467 | 2.3M USD | −87.8% |
| D. E. Shaw & Co. | Held (±25%) | 6,724 | 954K USD | +20.1% |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
Have members of Congress traded Neurocrine Biosciences (NBIX)?
The most recent congressional trade disclosed in Neurocrine Biosciences is a sale by Lisa C. McClain (house, MI), dated 17 Jun 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 17 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 57 days |
| 11 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 63 days |
What has been filed or recorded for Neurocrine Biosciences (NBIX)?
The filings we hold for Neurocrine Biosciences, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 20 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,639 shares | 909K USD notional · 0.007% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 891 shares | 126K USD notional · 0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 143 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 1.96 USD | |
| 30 Sep 2026 | Financials | Total assets | 5.6B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 3.9B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 1.39 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 1.91 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 4.67 USD | |
| 31 Dec 2025 | Financials | Revenue | 2.9B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 478.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 4.67 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 2.04 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 1.06 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.08 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 3.29 USD |
What do people ask about Neurocrine Biosciences (NBIX)?
What did Neurocrine Biosciences shares close at?157.00
Neurocrine Biosciences closed at 157.00 USD on 10 Sep 2026, up 1.21% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Neurocrine Biosciences’ market cap?15.9B
Neurocrine Biosciences is worth 15.9B USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Neurocrine Biosciences’ P/E ratio?23.3
Neurocrine Biosciences has a price-to-earnings ratio of 23.3, as of 10 Sep 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Neurocrine Biosciences’ revenue?2.9B
Neurocrine Biosciences reported revenue of 2.9B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Neurocrine Biosciences insiders bought or sold shares recently?6 sales
In the 90 days to 17 Nov 2026, Neurocrine Biosciences insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase. A further 27 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Neurocrine Biosciences?12 of 45
12 of the 45 funds we track reported a Neurocrine Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Man Group. See Funds
Have members of Congress traded Neurocrine Biosciences?2 trades
Yes. 2 trades in Neurocrine Biosciences appear in the congressional disclosures we hold; the latest is a sale by Lisa C. McClain (House, MI) dated 17 Jun 2025, filed 13 Aug 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Neurocrine Biosciences last report earnings?1.96
Neurocrine Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 1.96 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Lisa C. McClain: Office of Congresswoman Lisa McClain, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings